The novel 5-lipoxygenase inhibitor ABT-761 attenuates cerebral vasospasm in a rabbit model of subarachnoid hemorrhage by Barbosa, MD et al.
EXPERIMENTAL STUDIES
The Novel 5-Lipoxygenase Inhibitor ABT-761 Attenuates
Cerebral Vasospasm in a Rabbit Model of
Subarachnoid Hemorrhage
Marcos D. Barbosa, M.D., Adam S. Arthur, M.D.,
R. Hunter Louis, B.A., Timothy MacDonald, Ph.D.,
Richard S. Polin, M.D., Christine Gazak, M.P.H.,
Neal F. Kassell, M.D.
Department of Neurological Surgery, Virginia Neurological Institute (MDB, RHL,
RSP, NFK), and Department of Chemistry (TM), University of Virginia, Charlottesville,
Virginia, and Departments of Neurological Surgery and Family and Preventive
Medicine (ASA, CG), University of Utah, Salt Lake City, Utah
OBJECTIVE: Eicosanoids have been implicated in the pathogenesis of cerebral vasospasm after subarachnoid hemorrhage
(SAH). Leukotrienes, 5-hydroxyperoxyeicosatetraenoic acid, and 5-hydroxyeicosatetraenoic acid are part of this group
of substances, resulting from the 5-lipoxygenase activity on arachidonic acid metabolism. This study examined the
effects of ABT-761, a new 5-lipoxygenase inhibitor, on cerebral vasospasm in an in vivo rabbit model of SAH.
METHODS: A total of 48 rabbits were assigned to one of six groups: SAH  placebo (n  8), SAH  ABT-761 20
mg/kg (n  8), SAH  ABT-761 30 mg/kg (n  8), control  placebo (n  8), control  ABT-761 20 mg/kg (n
 8), and control  ABT-761 30 mg/kg (n  8). Drug administration was initiated 30 minutes after induction of
SAH and repeated 24 hours later. The animals were killed 48 hours after SAH, using the perfusion-fixation
method. The cross sectional areas of basilar artery histological sections were measured by an investigator blinded
to the treatment groups of the individual samples.
RESULTS: In placebo-treated animals, the average luminal cross sectional area of the basilar artery was reduced by 68%
after SAH as compared with controls (P < 0.0001). After SAH, the vasospastic response was attenuated in animals
treated with 20 or 30 mg/kg representing a 28 or 35% reduction, respectively (P  0.0011 and P  0.0038).
CONCLUSION: The results demonstrated that ABT-761 is effective in attenuating experimental cerebral vasospasm,
indicating that this new drug represents a potential therapeutic agent for the treatment of vasospasm after SAH.
(Neurosurgery 49:1205–1213, 2001)
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Cerebral vasospasm is the most important cause of mor-bidity and mortality in patients surviving subarach-noid hemorrhage (SAH), as it can compromise cerebral
hemodynamics and lead to the development of delayed isch-
emic neurological deficits (7, 18, 53). The mechanism of cere-
bral vasospasm is still unclear, but is likely to involve a
complex chain of events involving inflammatory processes
taking place in the arterial wall (6, 7, 15, 18, 51).
The metabolism of arachidonic acid undergoes pathological
changes after SAH and provides substrate for the cyclooxy-
genase and lipoxygenase pathways. Prostaglandins and
thromboxane are produced in the first pathway. Leukotrienes,
hydroxyperoxyeicosatetraenoic (HPETE) acid, and hydroxy-
eicosatetraenoic (HETE) acid result from lipoxygenase activity
in the second pathway (14, 21, 39, 40). The products of both
pathways are inflammatory mediators and have been shown
to have vasoactive properties. 5-lipoxygenase activity is en-
hanced after an SAH; this increased activity may be signifi-
cant in the pathogenesis of cerebral vasospasm (44, 54). If so,
the administration of an inhibitor should ameliorate experi-
mental cerebral vasospasm after SAH.
To test this hypothesis, we evaluated the potential thera-
peutic value of the new compound ABT-761 after SAH-
induced vasospasm in the rabbit model. This compound is a
1205Neurosurgery, Vol. 49, No. 5, November 2001
potent and selective 5-lipoxygenase inhibitor with extended
duration of action. It has a molecular weight of 318.37; the
molecular formula is C16H15FN2O2S. ABT-761 has been
shown to attenuate experimental bronchoconstriction and
pulmonary inflammation (2), but has not been tried in the
context of cerebral vasospasm.
MATERIALS AND METHODS
Overview
Forty-eight male New Zealand White rabbits weighing 3.0
to 4.0 kg each were assigned to one of six groups. Rabbits in
the SAH groups were killed 48 hours after SAH was induced,
and those not subjected to SAH were killed 48 hours after the
initiation of placebo or ABT-761 administration. Group 1 an-
imals (SAH  placebo) were subjected to SAH and given a
placebo (n  8). Group 2 animals (SAH  drug 20 mg/kg)
were subjected to SAH and given ABT-761 (n  8). Group 3
animals (SAH  drug 30 mg/kg) were also subjected to SAH
and given ABT-761 (n  8). Group 4 animals (control 
placebo) were not subjected to SAH and were given a placebo
(n  8). Group 5 animals (control  drug 20 mg/kg) were not
subjected to SAH but were given ABT-761 (n  8). Group 6
animals (control  drug 30 mg/kg) were not subjected to
SAH but were given ABT-761 (n  8).
SAH, perfusion-fixation, embedding, and morphometry
were performed as described previously and below. All ex-
perimental protocols were approved by the University of
Virginia Animal Research Committee.
ABT-761 administration
In Group 1 animals (SAH  placebo), a placebo was ad-
ministered 30 minutes after hemorrhage and repeated 24
hours later. ABT-761 was administered as an oral suspension
in a dose of 20 mg/kg or 30 mg/kg in 4 ml/kg of vehicle
(methylcellulose 0.2% in water). In Group 2 and 3 animals
(SAH  drug), ABT-761 was given 30 minutes after hemor-
rhage and repeated 24 hours later. Group 5 and 6 animals
(control  drug) received ABT-761 at the start of the study
period and then 24 hours later. Group 4 animals (control 
placebo) received a placebo (methylcellulose 0.2% in water)
on the same schedule.
Induction of SAH
Animals in Groups 1, 2, and 3 were anesthetized with an
intramuscular injection of a mixture of ketamine (40 mg/kg)
and xylazine (8 mg/kg) and endotracheally intubated. The
central ear artery was cannulated to obtain 5 ml of autologous
arterial blood. A 23-gauge butterfly needle was inserted per-
cutaneously into the cisterna magna, and 5 ml of autologous
blood was injected during a 20-second period. To facilitate the
settling of blood in the basal cisterns, the animals were posi-
tioned with their heads down for 20 minutes. They were
monitored closely for respiratory distress and, if necessary,
placed on a ventilator until spontaneous respiration resumed.
The animals were extubated and returned to their cages when
fully awake; during the next 48 hours, they were allowed free
access to food and water and were observed closely for ade-
quate food intake and for any possible neurological deficits.
Perfusion-fixation
Animals were anesthetized and intubated at the 48th hour
of the study period as described above, and cerebrospinal
fluid (CSF) was collected from the cisterna magna for deter-
mination of the ABT-761 concentration. The animals were
then paralyzed with pancuronium bromide (0.3 mg/kg) and
mechanically ventilated. The central ear artery was cannu-
lated for recording arterial pressure via an arterial line trans-
ducer. Arterial blood gas tension was measured and ventila-
tion parameters adjusted accordingly to maintain arterial pO2
and pCO2 within the physiological range. After satisfactory
respiratory parameters under anesthesia were established, the
thorax was opened and a cannula was placed in the aorta via
the left ventricle. The right atrial appendage was opened and
the descending thoracic aorta clamped. The vascular system
was perfused with 300 ml of Hanks’ balanced salt solution
(Sigma Chemical Co., St. Louis, MO) (pH 7.4 at 37°C) followed
by 500 ml of 1% paraformaldehyde and 1.5% glutaraldehyde
fixative in Hanks’ balanced salt solution. Perfusion was per-
formed at a pressure of 75 mm Hg in all groups. After
perfusion-fixation, the brainstem was removed, placed in the
same fixative solution, and stored at 4°C overnight. Animals
that showed incomplete subarachnoid clot or had residual
blood in the vasculature suggesting an inadequate perfusion
were excluded from the study at this point. Clot grading and
exclusion were performed by an investigator blinded to the
treatment group of the individual animals.
Embedding
After fixation, the basilar artery was removed from the
brainstem and the proximal third of the vessel was cut into
segments 2 mm in length. The tissue samples were washed
several times in 0.1 mol/L phosphate buffer, postfixed in 1%
osmium tetroxide in 0.1 mol/L phosphate buffer (pH 7.4) for
1 hour at room temperature, and washed again in phosphate
buffer. The tissue was dehydrated through a series of graded
ethyl alcohol solutions followed by propylene oxide. The
samples were placed in a 1:1 mixture of propylene oxide and
epoxy resin overnight; the next day, they were flat embedded
in 100% epoxy resin and allowed to polymerize at 60°C for 48
hours. Cross sections of the basilar artery (0.5 m thick) were
cut on a Reichert Ultracut E ultramicrotome (Vienna, Austria)
and mounted on glass slides.
Morphometry
Morphometric measurements of three randomly selected
arterial cross sections from each animal were performed using
the Image 1 Analysis System (Universal Imaging, West Ches-
ter, PA). Basilar artery cross sectional area was measured by
an investigator blinded to the treatment groups of the indi-
vidual arteries. The luminal area was calculated from the
perimeter of the internal elastic lamina and the area contained
within the boundaries of the internal elastic lamina. Three
measurements were taken from randomly selected cross sec-
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tions of each basilar artery. The luminal area for each basilar
artery was obtained by averaging these three measurements.
Determination of ABT-761 CSF concentration
CSF samples were collected at the 48th hour (before
perfusion-fixation) and centrifuged; the CSF was removed
and stored frozen until assayed. The frozen samples were
thawed, two volumes of methanol were added, and precipi-
tated CSF proteins were removed by centrifugation. Superna-
tants were injected directly onto a C18 reversed-phase column
(Adsorbo sphere HL 7-m column) and underwent chroma-
tography with a mobile phase composed of 55% acetonitrile
containing 10 mmol/L of acetohydroxamic acid and 8
mmol/L of triethylamine acetate (pH 6.5) at a flow rate of 1
ml/min. Peaks corresponding to ABT-761 were quantified by
ultraviolet absorbance at 260 nm using an external calibration
curve.
Statistical analysis
A Kruskal-Wallis one-way analysis of variance was per-
formed on the entire data set of morphometric measurements.
Pairwise multiple comparison post hoc analysis was per-
formed using the Bonferroni-Dunn method. Partial correla-
tion coefficients were performed on CSF ABT-761 concentra-
tion values by treatment groups.
RESULTS
The cross sectional areas of the basilar artery of individual
animals are shown in Table 1, and a graphical representation
of the mean values for each group is presented in Figure 1.
Figure 2 shows photographic examples of basilar artery cross
sections from Group 1 (SAH  placebo) and 2 (SAH  20
mg/kg) animals. A Kruskal-Wallis one-way analysis of vari-
ance was performed on the entire data set, which passed the
normality test (P  0.501) and the equal variance test (P 
0.097) and demonstrated statistical significance at the level of
P  0.01. SAH elicited a reduction in vascular area of 68% in
the placebo-treated animals (Group 1) as compared with con-
trols (Group 4). In contrast, the reduction in cross sectional
area in animals treated with ABT-761 was 28% in Group 2 and
35% in Group 3. Although data from Group 2 represent a
TABLE 1. Cross Sectional Area of Basilar Arteries of Individual Animals (mm2)a
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
SAH  Placebo SAH  D20 SAH  D30
Control 
Placebo
Control  D20 Control  D30
0.124 0.250 0.395 0.356 0.416 0.669
0.127 0.371 0.403 0.462 0.414 0.434
0.239 0.239 0.180 0.424 0.496 0.489
0.076 0.460 0.305 0.357 0.525 0.433
0.129 0.073 0.139 0.505 0.536 0.437
0.081 0.281 0.077 0.485 0.482 0.374
0.199 0.380 0.492 0.492 0.546 0.457
0.144 0.490 0.302 0.418 0.302 0.545
Mean  SD 0.140  0.553b 0.318  1.355c 0.287  1.438d 0.437  0.586 0.465  0.828e 0.480  0.909f
a SAH, subarachnoid hemorrhage; D20, ABT-761 20 mg/kg; D30, ABT-761 30 mg/kg; SD, standard deviation.
b Different from Group 4 (P < 0.0001).
c Different from Group 1 (P  0.0011).
d Different from Group 1 (P  0.0038), not different from Group 2 (P  0.6522).
e Not different from Groups 4 (P  0.5935) and 6 (P  0.7668).
f Not different from Group 4 (P  0.4077).
FIGURE 1. Graph depicting the effect of ABT-761 treatment
on arterial narrowing induced by SAH. The values represent
the mean  standard error for each treatment group.
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statistically significant reduction in the vasospastic response
observed as compared with Group 1 (P  0.0011), data from
Group 3 fell just short of statistical significance at P  0.0038,
with significance represented by P  0.0033. It is noteworthy
that the values obtained for animals treated with ABT-761 but
not subjected to SAH (Groups 5 and 6) did not differ signif-
icantly from the untreated control animals (P  0.5995 and P
 0.4077), indicating that the drug is not a simple vasodilator.
Table 2 shows the concentration of CSF ABT-761, verifying
that the drug appears in the subarachnoid space. Partial cor-
relation coefficients between treatment groups were not sta-
tistically significant. Figure 3 displays the mean CSF ABT-761
concentration by treatment group. Figure 4 is a scatterplot of
CSF ABT-761 concentration versus basilar artery cross sec-
tional area.
DISCUSSION
Cerebral vasospasm remains a major complication after an
SAH and, despite intensive studies, its precise mechanism is
not yet fully understood. Several putative spasmogens have
been shown to be active in the development of cerebral vaso-
spasm (7, 15, 18, 53). It has been established that an inflam-
matory reaction occurs after SAH (13, 57). This local process
takes place in the arterial wall and in the subarachnoid space
and may induce structural changes within the arterial wall
that contribute to the development of cerebral vasospasm (6,
15, 18, 26–28, 34, 51).
It has been proposed that hemoglobin released from the
subarachnoid blood clot induces the production of arachi-
donic acid metabolites, inflammatory mediators that have
direct vasoactive effects (47). Several studies reported the
possible involvement of arachidonic acid metabolism prod-
ucts in the development of vasospasm. Initially, eicosanoids
produced by the activity of cyclooxygenase-prostaglandins,
thromboxane, and prostacyclin were the subject of scrutiny in
the vasospasm literature (7, 9, 24, 35, 41, 43, 52, 56). More
recently, other eicosanoids resulting from the lipoxygenase
pathway, such as leukotrienes, HPETE acid, and HETE acid,
FIGURE 2. Photomicrographs of representative cross sec-
tions of the basilar artery corresponding to Group 1 (SAH 
placebo) (A) and Group 2 (SAH  drug 20 mg/kg) (B ).
TABLE 2. Cerebrospinal Fluid ABT-761 Concentrations (mol/L)a
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
SAH 
Placebo
SAH  20 mg SAH  30 mg Control  Placebo Control  20 mg Control  30 mg
0.00 0.31 0.42 0.00 0.25 0.91
0.00 0.31 0.35 0.00 0.25 0.66
0.00 0.29 0.52 0.00 0.53 0.70
0.00 0.23 0.21 0.00 0.36 0.78
0.00 0.40 0.25 0.00 0.35 1.69
0.00 0.42 1.97 0.00 0.36 0.92
0.00 0.57 0.00 0.47 1.70
1.75
Mean 0.00 0.32 0.75 0.00 0.36 1.05
a SAH, subarachnoid hemorrhage; 20 mg, ABT-761 20 mg/kg; 30 mg, ABT-761 30 mg/kg.
FIGURE 3. Bar graph depicting the concentration of ABT-
761 in CSF by the treatment group, demonstrating drug pen-
etration in the CSF space.
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have received more interest (10, 19, 20, 23, 25, 33–35, 44, 48–50,
54, 59).
Leukotrienes, HPETE acid, and HETE acid are formed by
the activity of 5-lipoxygenase. This enzyme catalyzes both the
transformation of arachidonic acid in 5-HPETE acid and of
5-HPETE acid in leukotriene A4, the common precursor of
leukotrienes. Leukotriene A4 produces leukotriene B4 and
leukotriene C4; leukotriene C4 is transformed into leukotriene
D4 and leukotriene E4 (14, 21, 39, 40). Leukotrienes, HPETE
acid, and HETE acid have large-action variabilities that in-
clude vasoconstrictor properties, prostacyclin synthesis inhi-
bition, platelet aggregation inhibition, promotion of neutro-
phil and eosinophil chemotaxis, activation of lymphocytes,
increases in vascular permeability, and the induction of en-
zyme release.
Several studies have shown that leukotrienes and other
lipoxygenase products have vasoconstrictor properties on
vascular beds (29, 32, 36), including cerebral arterial beds both
in vitro and in vivo (17, 30, 36, 46). These substances are
produced in the brain by cerebral arteries and by neurons (8,
10, 17, 19, 23, 30, 44, 59).
The production of leukotrienes is elevated in SAH (9–11, 19,
20, 23, 25, 33, 34, 44, 45, 50, 55, 59), and CSF levels are related
to the presence of vasospasm (12, 20, 25, 45, 55). The subarach-
noid blood clot itself produces leukotrienes (34, 59). In addi-
tion, leukocytes released from the blood clot or infiltrating the
arterial wall produce leukotrienes in a self-maintaining man-
ner, allowing leukotrienes to exert their vasoconstrictor effect
for a longer period of time (9, 10, 23, 25, 39). 5-lipoxygenase
activity is also enhanced in SAH (44).
It can be assumed that the development of cerebral vaso-
spasm is a complex problem, with many systems interacting
with various components of the blood, vessel wall, and sub-
arachnoid space. SAH stimulates arachidonic acid metabo-
lism, and the leukotrienes, HPETE acid, and HETE acid pro-
duced in the 5-lipoxygenase pathway may contribute to the
induction of cerebral vasospasm via a variety of mechanisms.
These include a direct vasoconstrictor effect on cerebral arter-
ies as a result of the following: activation of phospholipase C,
which induces intracellular calcium mobilization; the direct
action of cysteinyl leukotrienes, HPETE acid, and HETE acid;
the stimulation of free radical production by the reduction of
5-HPETE acid to 5-HETE acid; the antagonism of the vasodi-
latory effects of prostacyclin by the activity of leukocytes
attracted by leukotriene B4; and the promotion of an inflam-
matory reaction in the arterial wall and in the subarachnoid
space. The inflammatory response resulting from the leuko-
cyte infiltration of the arterial wall further promotes the re-
lease of lipoxygenase products and modifies the normal struc-
ture of the vessel, possibly sustaining a self-maintaining
reaction that leads to chronic vasospasm (10).
Although the cyclooxygenase pathway may also be impli-
cated in the pathogenesis of cerebral vasospasm through in-
hibition of prostacyclin synthesis and an increase in prosta-
glandin and thromboxane production, it seems unlikely that
an imbalance between prostacyclins and prostaglandins or
thromboxanes (3, 12, 24, 35, 41) is the key factor in the patho-
genesis of cerebral vasospasm (7, 11, 22, 43). The products of
5-lipoxygenase may play a more important role than the
products of cyclooxygenase in the development of cerebral
vasospasm after SAH.
Despite recognition of the potential importance of lipoxy-
genase products in cerebral vasospasm, their precise role has
not been defined. The development of new agents capable of
interfering with the synthesis or action of these potent sub-
stances may help to more fully explore this issue. Lipoxygen-
ase synthesis inhibitors (1, 4, 5, 8, 16, 31, 37, 38, 42, 58, 60) and
leukotriene receptor antagonists (17, 20, 29, 31, 36, 38) have
been shown to inhibit the action of leukotrienes and/or
HPETE and HETE acids. In a few cases, this therapeutic
strategy has shown some potential to prevent the develop-
ment of delayed cerebral vasospasm after experimental SAH
(20, 49, 58).
To test the hypothesis that the 5-lipoxygenase pathway plays a
significant role in the development of cerebral vasospasm, we stud-
ied the effect of ABT-761 ([R]-N-[3-{5-{4-fluorophenylmethyl}thien-
2yl}-1-methyl-2-propynyl]-N-hydroxyurea) in an experimental
model of SAH-induced cerebral vasospasm. This agent is a po-
tent and selective inhibitor of leukotriene formation both in vitro
and in vivo. ABT-761 is a second-generation 5-lipoxygenase
inhibitor, is more potent than other N-hydroxyureas containing
5-lipoxygenase inhibitors, and has excellent pharmacokinetic
characteristics (2, 4). The precise mechanism by which
N-hydroxyurea compounds inhibit 5-lipoxygenase activity has
not yet been defined, but the fact that this inhibition is reversible
and independent of preincubation time indicates that there is not
a covalent interaction of the compound with the enzyme. It is
possible that the hydroxamic acid moiety (N-hydroxyurea) com-
plexes with the iron atom at the active site of the enzyme. It
selectively blocks the formation of 5-HPETE and its transforma-
tion in leukotriene A4 and, consequently, inhibits the synthesis of
all other leukotrienes and 5-HETE acid (1, 4). It has a weakly
FIGURE 4. Graph showing the concentration of ABT-761 in
CSF versus the basilar artery cross sectional area. A trend
toward segregation of SAH versus control animals can be
seen.
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inhibitory effect on other eicosanoid-metabolizing enzymes,
such as 12- and 15-lipoxygenase and cyclooxygenase (2). The use
of this potent and specific 5-lipoxygenase inhibitor is therefore
theoretically capable of attenuating the vascular effects of the
5-lipoxygenase products of arachidonic acid metabolism.
It is interesting that a greater effect is noted in the group
treated with 20 mg/kg of ABT-761 than in the group treated
with 30 mg/kg, although the difference between the differ-
ence was not statistically significant. The cross sectional area
of the basilar artery in the group treated with 30 mg/kg
(Group 3) certainly shows a strong trend toward attenuation
of vasospasm. ABT-761 is a highly selective inhibitor of
5-lipoxygenase, but it is possible that the lessened effect at a
higher dosage indicates saturation of available 5-lipoxygenase
with a spillover inhibition of other arachidonic acid pathway
catalysts, causing a corresponding decrease in the production
of endogenous vasodilatory substances. Further studies are
planned to elucidate the maximally effective dosage of the
compound and to establish a dose-response curve.
CSF ABT-761 concentration values are displayed in Table 2
and Figure 3. Correlation coefficients among the treatment
groups did not show statistical significance; however, we
think that it is important that drug penetration into the CSF
space is demonstrated. The range of CSF ABT-761 concentra-
tions were much greater in Groups 3 and 6 (SAH 30 mg/kg
and control  30 mg/kg, respectively) than in Groups 2 and
5 (SAH  20 mg/kg and control  20 mg/kg, respectively).
This trend toward a greater variability of CSF concentration
may represent a saturation or clearance effect. This, coupled
with the lessened effect on basilar artery area in Group 3,
raises some interesting pharmacodynamic issues for future
study.
Figure 4 depicts the concentration of CSF ABT-761 plotted
against the cross sectional area of the basilar artery. A trend
toward segregation of SAH versus control animals is appar-
ent. The concentration of ABT-761 in control animals is highly
variable, although the cross sectional area of the basilar artery
remains fairly consistent. Conversely, the concentration of
ABT-761 in SAH animals is usually less than 0.3 mol/L;
however, the cross sectional area of the basilar artery is highly
variable. Variability in the cross sectional area is expected in
SAH groups; not all hemorrhaged animals achieve the same
degree of vasospasm. The greater degree of variability in drug
concentration among control animals may indicate a trend
toward variable drug utilization in the SAH animals than in
the control animals.
The results of this study demonstrate that ABT-761, when
administered orally once a day for 48 hours, can be of value in
reducing the vasospastic arterial response after SAH. Al-
though both dosages studied achieved statistical significance,
more studies are needed to establish the dose-response curve
and to define the maximally effective dose. It is also necessary
to delineate the potential side effects with short-term admin-
istration and to clarify the window of therapeutic benefit as
well as the efficacy of other administration routes.
This study represents a test of concept and establishes the
potential utility of this family of compounds for this applica-
tion. Primate studies are needed to clarify whether second-
generation 5-lipoxygenase inhibition has a potential role in
the treatment of clinical cerebral vasospasm.
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COMMENTS
The authors have evaluated a new selective 5-lipoxygenase
inhibitor, ABT-761, in a rabbit model of subarachnoid hemor-
rhage (SAH). They demonstrated a reduction in the amount of
vascular narrowing in treated animals. Arachidonic acid me-
tabolism by the 5-lipoxygenase pathway produces leukotri-
enes, hydroxyperoxyeicosatetraenoic acid, and hydroxyeico-
satetraenoic acid. Yokota et al. (1) showed angiographic
evidence of reduced spasm after inhibition of 5-lipoxygenase
in a canine model implicating this enzyme in the pathogenesis
of cerebral vasospasm. Subsequent studies have suggested
that the 5-lipoxygenase enzyme is absent in homeostatic con-
ditions and is induced by SAH, making this an attractive
target for intervention. With this study and others reported in
the literature, we agree with the authors that sufficient evi-
dence exists to justify primate studies on the effect of





1. Yokota M, Tani E, Maeda Y, Kokubu K: Effect of 5-lipoxygenase
inhibitor on experimental delayed cerebral vasospasm. Stroke 18:
512–518, 1987.
The authors have demonstrated an antivasospastic action
of an inhibitor of 5-lipoxygenase (ABT-761) in a rabbit model
of SAH. The drug is reported to be a relatively specific inhib-
itor of this enzyme, although a demonstration of inhibition of
the enzyme in the cerebral arteries of treated animals as
compared with controls and of the lack of inhibition of similar
but distinct enzymes would provide additional supportive
evidence. Furthermore, a reduction in products of the enzyme
and/or inflammation in the subarachnoid space would lead
to more support for the authors’ thesis that products of
5-lipoxygenase mediate vasospasm in this model. An excel-
lent and comprehensive review of the literature followed that
is constructed to support a role for altered eicosanoid metab-
olism and inflammation in the genesis of vasospasm. This
reviewer thinks that such lipid mediators and free radical
reactions are likely to be very important in the genesis of
vasospasm, although the role of “inflammation” is unclear.
There is a superficial resemblance between discussion of the
role of inflammation in this article and its role in the patho-
genesis of cerebral blood flow changes in bacterial meningitis
(2). Inflammation is a complex biological response that may
have beneficial and/or detrimental effects, depending, for
example, on the specific type of inflammation that is induced
and on the time after hemorrhage (1). As the complexity of
these responses becomes clearer, the pathogenesis of vaso-
spasm may as well.
R. Loch Macdonald
Chicago, Illinois
1. Feuerstein GZ, Wang X, Barone FC: The role of cytokines in the
neuropathology of stroke and neurotrauma. Neuroim-
munomodulation 5:143–159, 1998.
2. Leib SL, Täuber MG: Pathogenesis of bacterial meningitis. Infect
Dis Clin North Am 13:527–548, 1999.
Barbosa et al. have used their well-characterized rabbit
model of SAH to examine the potential for a 5-lipoxygenase
inhibitor (ABT-761) to diminish vasospasm after SAH. They
have made several findings. The orally administered drug
attains significant concentrations in the cerebrospinal fluid,
and ABT-761 seems to diminish cerebral vasospasm at doses
of 20 mg/kg. The authors did not find a dose-dependent
reduction in the vasospasm, indicating that this complex sys-
tem may be affected in a biphasic way by the administration
of the 5-lipoxygenase inhibitor. The discussion of this article
regarding the multifaceted pathophysiology of cerebral vaso-
spasm is quite instructive. The thoughtful discussion of this
complex topic and the nicely controlled experiments pre-
sented here suggest that this pharmacological strategy may
1212 Barbosa et al.
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well be effective in attenuating cerebral vasospasm in human
patients.
Ralph G. Dacey, Jr.
St. Louis, Missouri
The cysteinyl leukotrienes C4, D4, and E4 are synthesized de
novo from arachidonic acid via the activity of 5-lipoxygenase
and a membrane-bound 5-lipoxygenase-activating protein (3).
The effects of the cysteinyl leukotrienes are mediated via Gq
protein-coupled receptors (5). Four major strategies have been
followed in the search for drugs that inhibit the release or
effects of the leukotrienes: phospholipase A2 inhibitors,
5-lipoxygenase inhibitors, 5-lipoxygenase-activating protein
inhibitors, and cysteinyl-leukotrienes receptor antagonists.
Several potent and selective inhibitors of the first three classes
of compounds have been identified and many of these have
been in clinical trial for asthma treatment. Some of the
5-lipoxygenase inhibitors have shown impressive activity in
clinical trials, which has highlighted the role of these media-
tors in asthma (1, 2). The 5-lipoxygenase inhibition has also
been shown to be effective in both attenuating the synthesis of
leukotrienes and in ameliorating cerebral vasospasm in the
two-hemorrhage canine model (4, 6). The study presented
here by Barbosa et al. provides further evidence for the effec-
tiveness of the 5-lipoxygenase inhibitors in attenuating exper-
imental cerebral vasospasm. In these studies, a novel and
selective 5-lipoxygenase antagonist, ABT-761, administered
once a day for 48 hours, was effective in attenuating vaso-
spasm in a rabbit model of SAH. What is lacking that would
make the hypothesis of the authors more appealing is a study
of the levels of the leukotrienes and/or determination of
5-lipoxygenase activity in the cerebrospinal fluid that causally
links the effects of ABT-761 to cerebral vasospasm. Further-
more, there is little relevance to the chronic cerebral vaso-
spasm, which is maintained for several days. Obviously, fur-
ther studies will be required to address these issues. Another
important point is the authors’ observation that ABT-761
seemed to be less effective when administered in a higher
dose. One appealing possibility is that inhibition of
5-lipoxygenase activity with higher concentrations of the
agent may increase the availability of the substrate arachi-
donic acid for cyclooxygenase action and the subsequent gen-
eration of vasoconstrictive products of this enzyme, thus con-
tributing to the increase in vascular tone and diminished
effectiveness of ABT-761. Certainly, ABT-761 efficacy in the
treatment of chronic cerebral vasospasm must be addressed
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